title: Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
abstract: CONCLUSIONS
  In platinum–taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness.
  
  
  METHODS
  Between 2004 and 2013, patients afflicted with platinum–taxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m2 on the 1st, 8th and 15th days, every 28 days, were examined retrospectively.
  
  
  RESULTS
  Twenty-six patients with platinum–taxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinum–taxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinum–taxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinum–taxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate.
  
  
  CONCLUSIONS
  Second- and third-line gemcitabine at a dose of 1,250 mg/m2 on days 1, 8 and 15 every 28 days as a 30-minute i.v. infusion in platinum–taxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.
authors.forename: Hilmi
authors.initials: H
authors.lastname: Kodaz
authors.forename: Ilhan
authors.initials: I
authors.lastname: Hacibekiroglu
authors.forename: Esma
authors.initials: E
authors.lastname: Turkmen
authors.forename: Bulent
authors.initials: B
authors.lastname: Erdogan
authors.forename: Cagnur
authors.initials: C
authors.lastname: Elpen
authors.forename: Sernaz
authors.initials: S
authors.lastname: Uzunoglu
authors.forename: Irfan
authors.initials: I
authors.lastname: Cicin
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D017671:Platinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D017671:Platinum Compounds; D043823:Taxoids; D003841:Deoxycytidine; D000093542:Gemcitabine